Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21-99
SponsorNational Heart Centre Singapore

About this trial

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.

Eligibility criteria

Qualifiers

Age 21 years and above

No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)

No history of cancer

Able and willing to comply with study procedures and provide signed informed consent

Disqualifiers

Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)

Unstable medical conditions (such as symptomatic heart failure, unstable hypertension/glucose levels as determined by investigators, symptomatic arrhythmias, angina)

Pregnant or nursing women

Known allergies to pyruvate or any of its components

Trial design

Treatments tested in this trial

  • Hyperpolarized 13C-pyruvate

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

National Heart Centre Singapore

Lead sponsor

National Medical Research Council (NMRC), Singapore

Collaborator